In the annual Research Round Up series, Cancer.Net Editorial Board members answer the question, “What was the most exciting or practice-changing research in your field presented at the 2023 ASCO Annual Meeting?” In this episode, 3 Cancer.Net Editorial Board members discuss new research presented at the meeting in treating non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), and mesothelioma.
Listen below, and subscribe to Cancer.Net Podcasts wherever you listen to podcasts for new episodes in this series.
Advancing treatment for lung cancer and mesothelioma
Dr. Charu Aggarwal, the 2023 Cancer.Net Associate Editor for Lung Cancer, leads a robust discussion with Dr. Melina Marmarelis, the 2023 Cancer.Net Specialty Editor for Mesothelioma, and Dr. Kristin A. Higgins, a 2023 Cancer.Net Lung Cancer Advisory Panelist, on advancements in treating lung cancer and mesothelioma. Together, they cover 6 studies, including:
-
The phase 3 ADAURA clinical trial, which studied whether giving the targeted therapy drug osimertinib (Tagrisso) after surgery could help people with stage IB to IIIA NSCLC with an epidermal growth factor receptor (EGFR) mutation live longer. [4:00]
-
The phase 3 KEYNOTE-671 clinical trial, which evaluated whether using the immunotherapy drug pembrolizumab (Keytruda) both before and after surgery could reduce the chances of the cancer coming back and help people with stage IIA, IIIA, and IIIB NSCLC live longer. [9:33]
-
The phase 3 IND227 clinical trial, which looked at whether adding pembrolizumab to chemotherapy could help people with pleural mesothelioma who did not receive surgery live longer. [14:55]
-
The phase 3 KEYNOTE-789 clinical trial, which examined whether adding pembrolizumab to chemotherapy affected outcomes for people with NSCLC with an EGFR mutation whose cancer had grown following treatment with a targeted therapy. [17:28]
-
The phase 2 SWOG S1929 clinical trial, which studied whether maintenance therapy with the immunotherapy drug atezolizumab (Tecentriq) in combination with the targeted therapy drug talazoparib (Talzenna) could delay cancer growth in people with extensive stage SCLC that tested positive for the biomarker Schlafen-11 (SLFN11). [20:30]
-
The phase 3 LUNAR clinical trial, which assessed whether adding tumor treating field therapy to standard treatment could help people with metastatic NSCLC live longer. During tumor treating field therapy, a noninvasive, wearable device is placed on the skin that produces an electrical field to help stop tumor cells from growing and spreading. [24:33]
Disclosure information for this podcast’s speakers can be found in their individual biographies linked to above.
Was this podcast useful? Please subscribe, rate, and review Cancer.Net Podcasts wherever you listen to podcasts. This prerecorded podcast can be listened to online or downloaded to your computer. A transcript is also available. For more information, visit the Cancer.Net podcast page.
Cancer.Net podcasts are edited for length and content.
